“
TL;DR
The central finding is that the selective RET inhibitors selpercatinib and pralsetinib have demonstrated potent efficacy and favorable toxicity profiles in clinical trials, offering a significant therapeutic advance.
Frontiers in Oncology · 7 authors, 6 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The central finding is that the selective RET inhibitors selpercatinib and pralsetinib have demonstrated potent efficacy and favorable toxicity profiles in clinical trials, offering a significant therapeutic advance.
The central finding is that the selective RET inhibitors selpercatinib and pralsetinib have demonstrated potent efficacy and favorable toxicity profiles in clinical trials, offering a significant therapeutic advance.